HomeCompareCHGCF vs EPRT

CHGCF vs EPRT: Dividend Comparison 2026

CHGCF yields 2.90% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCF wins by $350.21M in total portfolio value
10 years
CHGCF
CHGCF
● Live price
2.90%
Share price
$55.78
Annual div
$1.62
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.27M
Annual income
$328,490,171.71
Full CHGCF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CHGCF vs EPRT

📍 CHGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHGCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCF
Annual income on $10K today (after 15% tax)
$246.26/yr
After 10yr DRIP, annual income (after tax)
$279,216,645.95/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CHGCF beats the other by $279,205,731.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCF + EPRT for your $10,000?

CHGCF: 50%EPRT: 50%
100% EPRT50/50100% CHGCF
Portfolio after 10yr
$175.17M
Annual income
$164,251,506.21/yr
Blended yield
93.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CHGCF
No analyst data
Altman Z
21.8
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCF buys
0
EPRT buys
0
No recent congressional trades found for CHGCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCFEPRT
Forward yield2.90%3.92%
Annual dividend / share$1.62$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%29%
Portfolio after 10y$350.27M$63.4K
Annual income after 10y$328,490,171.71$12,840.73
Total dividends collected$348.65M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CHGCF vs EPRT ($10,000, DRIP)

YearCHGCF PortfolioCHGCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,279$579.45$11,205$505.18+$74.00CHGCF
2$13,291$1,221.65$12,672$682.46+$619.00CHGCF
3$16,912$2,690.62$14,490$930.48+$2.4KCHGCF
4$24,495$6,399.38$16,786$1,282.69+$7.7KCHGCF
5$43,534$17,324.98$19,753$1,791.56+$23.8KCHGCF
6$104,136$57,554.30$23,677$2,541.64+$80.5KCHGCF
7$368,757$257,331.25$29,008$3,672.99+$339.7KCHGCF
8$2,097,816$1,703,246.11$36,463$5,425.08+$2.06MCHGCF
9$20,356,014$18,111,350.35$47,238$8,221.57+$20.31MCHGCF
10$350,271,106$328,490,171.71$63,385$12,840.73+$350.21MCHGCF

CHGCF vs EPRT: Complete Analysis 2026

CHGCFStock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CHGCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCF vs SCHDCHGCF vs JEPICHGCF vs OCHGCF vs KOCHGCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.